ACAD Q4 2023 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$231M+69.3% YoY

Gross Profit

$213M92.3% margin

Operating Income

$35M15.1% margin

Net Income

$46M19.8% margin

EPS (Diluted)

$0.28

QoQ Revenue Growth

+9.1%

Cash Flow

Operating Cash Flow

$85M

Free Cash Flow

$85M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$749M

Total Liabilities

$317M

Stockholders' Equity

$432M

Cash & Equivalents

$189M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$231M	$136M	+69.3%
Gross Profit	$213M	$134M	+59.0%
Operating Income	$35M	-$46M	+175.9%
Net Income	$46M	-$42M	+209.8%